Biotech Pharmaceutical
Molecular Targeting Technologies, Inc. is a privately held, clinical stage biotech, developing targeted radiotherapeutics for rare cancers. MTTI has received an exclusive worldwide license from the National Institutes of Health to commercialize selected targeted radiopharmaceuticals covered by their Evans blue (EB) platform technology patents. MTTI is committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostic assets to improve human health, reduce healthcare costs and reward stakeholders